GlassScriptPhysician profile
Hannah Haskins
NPI 1891491577
$2,010.93
in general payments reported to CMS, 2019-2025
16 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $351 · 2024: $875 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $788.89 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.68 | 2023-2025 | Ofev, Jardiance |
| Amgen INC. | $209.81 | 2023-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $185.02 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $95.42 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $84.88 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Mallinckrodt Hospital Products INC. | $71.38 | 2023-2024 | Acthar |
| Pulmonx Corporation | $70.11 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Bayer Healthcare Pharmaceuticals INC. | $54.41 | 2023-2024 | |
| Novo Nordisk INC | $44.51 | 2024-2025 | Wegovy |
| Daiichi Sankyo INC. | $43.60 | 2023-2025 | Injectafer |
| Vanda Pharmaceuticals INC. | $42.80 | 2025 | Fanapt |
| Fresenius USA Marketing, INC. | $21.13 | 2024 | Velphoro |
| Electromed, INC. | $17.98 | 2023 | Smartvest |
| Philips North America LLC | $17.93 | 2024 | (Ak6) Vest Therapy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Haskins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.